Buck Institute for Research on Aging

DUBLIN--( BUSINESS WIRE )--The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016. There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments. Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal. Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project. The report provides a detailed understanding and analysis of how and why companies enter joint venture deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals. Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal. The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances. Key benefits Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release Comprehensive access to actual joint venture contracts entered into by the world's life science companies Insight into the terms included in a joint venture agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide. Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes: Trends in joint venture dealmaking in the biopharma industry since 2016 Case studies of real-life joint venture deals Comprehensive listing of joint venture deals since 2016 Access to joint venture contract documents The leading joint venture deals by value since 2016 Most active joint venture dealmakers since 2016 The leading joint venture partnering resources In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals. Companies Mentioned 3SBio 1717 Life Science Ventures A*STAR Agency for Science Technology and Research A*STAR Institute of Microelectronics (IME) A*STAR' Institute of Molecular and Cell Biology A2A Pharmaceuticals AAP Implantate AG Abbott Laboratories Abbvie Abilita Bio ABIVAX Abzena Accellix Accuray Acnos Pharma Adept Neuro Adisseo Advanced Prenatal Therapeutics Advanced Technologies Solutions Aequus Pharmaceuticals Agilis Biotherapeutics AgonOx AirWare Labs Aitbiotech Akers Biosciences AKESOgen Aleafia Health Aleva Neurotherapeutics Allied-Bristol Life Sciences Allied Minds Ally Bridge Group Altus Formulation Alzheimer's Association Alzheimer's Research UK Amarantus BioSciences Amendia American Diabetes Association AmerisourceBergen Amunix Amyris AnaBios Anokion Antitope Antoxerene Apax Partners Aphria Arbele Arbutus ARCH Personalized Medicine Initiative Aridis Pharmaceuticals Aruvant Sciences Arvinas Ascendance Biotechnology Ascendis Pharma Asklepios Biopharmaceutical Aslan Pharma Astellas Pharma AstraZeneca ATAI Life Sciences Athenex ATL Technology Atomwise Atrapos Therapeutics Atropos Therapeutics Auramedi Farmaceutica Autobio Diagnostics AUT Roche Diagnostics Laboratory AUT University Auxly Cannabis Group Avacta Avactis Biosciences Avalon GloboCare Avivagen Avvinity Therapeutics Axis Therapeutics Bain Capital Baxter International Bayer Baylor College of Medicine Baylor Miraca Genetics Laboratories B Braun B Braun CeGaT Beckley Canopy Therapeutics Beckley Foundation Becton Dickinson BeiGene Beijing Genomics Institute (BGI) Beijing Leadman Biochemistry Berry Genomics Betaliq BevCanna BGI Tech Solutions BHB Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAmber Biodist Biodyne USA BioFields Biogen Biohealth Innovation BioHeart BioLife Solutions BioLight BiolineRX biologistex CCM BioMed X Innovation Center Biomerics BioMotiv BioPharma Services Blackstone Blockshine Technology Bloomage BioTechnology Bloom Burton BLP Management Blueberries Medical Boehringer Ingelheim Breakthrough Diagnostics Brigham and Women's Hospital Bristol-Myers Squibb Broad Institute Buchang Pharmaceutical Buck Institute for Age Research Bukwang Pharmaceuticals Button Capital Calysta Energy Cancer Research Technology Cannabics Pharmaceuticals Cannabis Biocare Cannabis Therapeutics CannAmerica Brands CannaRoyalty Canopy Health Innovations Capna Intellectual Capnia Cardio3 Biosciences Asia Holdings Casebia Therapeutics Catapult Therapy TCR CB2 Therapeutics CBDerma Technology CBDistribution Cedar Gate Technologies CeGaT Cell Therapy Catapult Celyad Centauri Therapeutics Centene Center for Genetic Engineering and Biotechnology (Cuba) Centre for Commercialization of Regenerative Medicine (CCRM) Centro de Inmunolgia Molecular Cerevel Therapeutics Cesca Therapeutics Chan Soon-Shiong Institute of Molecular Medicine ChemAxon Children's Medical Research Institute Chimera Biotec China-Israel Biological Technology China-Singapore Guangzhou Knowledge City China Isotope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partners Cre8ive CRISPR Therapeutics CureCell Cyclica CytoBioscience Cytotheryx Cytovant Sciences Daewoong Pharmaceutical Dance Biopharm Dasman Diabetes Institute David Snow Deerfield Management DemeRx Demetra Denka Denka-KEW Genomics DepYmed DIAN Diagnostics Diavax Biosciences Dixi Dizal Pharmaceutical DolCas-Tenshi Bioceuticals DolCas Biotech Dona Blanca Dongbao Dr. Walter Bell Duke-NUS Graduate Medical School Singapore Eastar Industries Eastern Capital Easton Pharmaceuticals eCardio Diagnostics Eddingpharm Eden BioCell Elanix Biotechnologies Elevar Therapeutics Eli Lilly EMD Millipore EMD Serono Emergence Therapeutics EmoCellix Emory University Emosis Enigma Diagnostics Enova Illumination Entheogenix Biosciences ERS Genomics Evotec ExCellThera Exemplar Genetics Facebook Faes Farma Faxian Therapeutics Fedecore Fedora Pharmaceuticals FerGene Ferring Pharmaceuticals FJ Pharma Flexpoint Ford Flow Pharma Fonterra Food and Drug Administration (FDA) FORMA Therapeutics Fortress Biotech Fosun Pharmaceutical FoxBio Fox Chase Cancer Center Fraunhofer Institute for Microelectronic Circuits and Systems Frazier Healthcare Ventures Fresenius Kabi Pharmaceuticals Frontage Laboratories FSD Pharma Futura Medical Fuzionaire Diagnostics Fuzionaire Radioisotope Technologies G-treeBNT Galectin Sciences Galectin Therapeutics Galvani Bioelectronics Gauss Surgical Genentech Gene Therapy Research Institution Genetic Technologies Genevant Sciences Genome Institute of Singapore Genomix Scientific Gentag GeoVax German Research Center for Artificial Intelligence Gerresheimer GHO Capital Ginkgo BioWorks GlaxoSmithKline For more information about this report visit https://www.researchandmarkets.com/r/laae8e About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Ceremony Held Today in Zurich, Switzerland with Presentation by Dr. Rando and Keynote by Nobel Laureate Dr. Didier QuelozSAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fountain Therapeutics (“Fountain”), a biopharmaceutical company leveraging proprietary breakthroughs in artificial intelligence and computational modeling to target the biology of cellular resilience, today announced that Thomas Rando, M.D., Ph.D., co-founder and executive chairman of Fountain, is being honored in a ceremony held today in Zurich to receive the prestigious NOMIS Distinguished Scientist Award. The NOMIS Distinguished Scientist Award is presented to pioneering scientists who, through their innovative, groundbreaking research, have made a significant contribution to their respective fields and who inspire the world around them. Their bold ideas and unique approaches involve interdisciplinary collaboration and apply a broad range of methods, building bridges across the boundaries of disciplines. “We would like to congratulate Tom for being recognized with the NOMIS Distinguished Scientist Award,” said Anu Hoey, chief operating and business officer of Fountain. “Tom has been a pioneer and leader in the use of heterochronic parabiosis to study the role of blood and circulating factors in the biology of aging, and his work has demonstrated that factors in young serum can directly reverse many aspects of cellular and tissue aging. We are thrilled to benefit from his insights and groundbreaking research at Fountain for the development of promising innovative therapies for chronic degenerative diseases.” Dr. Rando is now focused on studying stem cell quiescence—a dormant, highly resilient state that enables long-term survival of stem cells. The research will provide unprecedented detail regarding the molecular regulation of stem cell quiescence as well as molecular insights into a cellular model of the evolutionary trade-off between survival and reproduction, a trade-off that is at the very core of the evolution of species. Thomas A. RandoDr. Rando has more than 20 years of experience in aging research and has published over 150 research articles on stem cell aging and tissue repair. Dr. Rando is the director of the UCLA Broad Stem Cell Research Center. At UCLA he is a professor in the Departments of Neurology and Molecular, Cell and Developmental Biology. Prior to joining UCLA, Dr. Rando served as the director of the Glenn Center for the Biology of Aging at Stanford University School of Medicine. While at Stanford, he was a professor of neurology and neurological sciences and deputy director of the Stanford Center on Longevity. Dr. Rando also served as chief of the neurology service and director of the Center for Regeneration, Repair, and Restoration (CTR3) at the Veterans Affairs Palo Alto Health Care System (VAPAHCS), where he was previously director of the Rehabilitation Research and Development Center of Excellence/REAP and Geriatric Research, Education and Clinical Center. Dr. Rando is a founding director of the Muscular Dystrophy Association clinic at the Stanford Medical Center. He actively serves as editor and board member of numerous scientific journals, including the Journal of Cell Biology, EMBO Journal, PLoS Biology and Aging Cell. Dr. Rando is a member of the American Academy of Arts and Sciences and the National Academy of Medicine and a fellow of the American Association for the Advancement of Sciences. Over the course of his career, Dr. Rando has received more than 40 award nominations. He is a former Paul Beeson Physician Faculty Scholar in aging, awarded by the American Federation for Aging Research and a former Ellison Medical Foundation senior scholar in aging. In 2005, he received an NIH Director’s Pioneer Award for his groundbreaking research in stem cell biology. He was also a member of the Advisory Council of the NIH’s National Institute of Aging, and holds board positions at numerous institutions, including Max Planck Institute for Biology of Ageing and the Buck Institute for Age Research. Dr. Rando serves on the scientific advisory board of several biotechnology and pharmaceutical companies, including NDLX Health Sciences and Novo Biosciences Inc. He previously served on the scientific advisory board of Fate Therapeutics. Dr. Rando received a B.A. from Harvard College, an M.D. from Harvard Medical School and a Ph.D. in Cell and Developmental Biology from Harvard University. About Fountain TherapeuticsFountain Therapeutics is a biopharmaceutical company building a pipeline of disease-modifying therapeutics to treat the underlying causes of chronic degenerative diseases. The company uses its deep insight into the biology of aging along with its proprietary AI-driven technology, which leverages recent developments in machine learning and computer vision, to extract cellular features that enable precise modeling of cellular resilience and health. Fueled by the expertise of leaders in aging research and computation, Fountain has turned these insights and technology into an unbiased, data-driven drug discovery and development engine. The company is advancing multiple programs to identify novel compounds, targets and disease biomarkers for the development of therapeutics to help the millions of patients affected by degenerative disease. For more information, please visit fountaintx.com and follow the company on Twitter @FountainTx or LinkedIn. ContactsAlexandra Santosasantos@wheelhouselsa.com Aljanae Reynoldsareynolds@wheelhouselsa.com

SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Keck Graduate Institute (KGI) and Cardea Bio, publicly congratulates the Chief Scientific Officer of Cardea Bio, Dr. Kiana Aran, for being awarded the Distinguished Engineer, Medal of Excellence award from Rutgers University. The Distinguished Engineer, Medal of Excellence award recognizes Dr. Aran for her research achievements in the field of bio-integrated electronics and her contribution to advancing the biomedical engineering field through her academic research at Keck Graduate Institute and her successful commercialization efforts that has brought her science and innovations to market. Dr. Kiana Aran reacts to the announcement by stating, "I am deeply honored for receiving this reputable award from Rutgers University, and I want to express my heartfelt appreciation to the many people that have helped me become the researcher I am today. Therefore, I want to pay it forward as my way of showing my gratitude. I will do that via our Aran Nebula Foundation where we help elevate other Excellent Female Scientists in the making." Dr. Brett Goldsmith, Chief Technology Officer at Cardea Bio, adds, "It is a pleasure to experience the scientific community acknowledging and supporting Dr. Aran's tremendous achievements. She has been instrumental in developing our BPU (Biosignal Processing Unit) platform and exciting applications using the BPU. What is best about Dr. Aran, though, is her inspiring activity and attitude toward science and engineering. She has an amazing positive impact on everyone at Cardea, KGI, and on scientists around the world!" The Distinguished Engineer award was established in 1960 and presented annually by the Rutgers Engineering Society to a fellow School of Engineering graduate who has made significant technical contributions in their career. Dr. Aran is only the second woman ever to win this award. In relation to the award, Rutgers University issued this statement, "Dr. Aran received her Ph.D. in biomedical engineering at Rutgers and continued her postdoctoral studies in bioengineering at UC Berkeley. She is a recipient of the National Institutes of Health postdoctoral training fellowship at the Buck Institute for Age Research and is a consultant for the Gates Foundation. Her efforts have also been recognized within the scientific community by the National Science Foundation's early career award, Clinical OMICs 10 under 40 Award, Athena Pinnacle Award in Life Sciences, and the prestigious Nature Research Awards for Inspiring Women in Science. In addition, Dr. Aran is also the recipient of numerous government grants to develop the next generation of electronic biosensors." Award event Honorees are celebrated at a networking dinner event that will be attended by alumni, faculty, and students, as well as an impressive representation of industry members and other distinguished guests. The Rutgers Engineering Society will give Dr. Kiana Aran the Distinguished Engineer "Medal of Excellence" at this event: Thursday, October 27, 2022, 6:00 PM to 9:00 PM - Cocktail Reception, Dinner and Award Presentations, at The Palace at Somerset Park, 333 Davidson Avenue, Somerset, NJ 08837. About Cardea Bio Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU™ (Biosignal Processing Unit). The BPU is the first and only semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea's rapidly expanding IP portfolio now has 29 broad patents issued and another 32 patents pending, cementing Cardea's market-leader position in the graphene biosensor industry, where they are bringing the BPU™ (Biosignal Processing Unit) Platform to market. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor technology for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. Contact Cardea Lasse Görlitz, VP of Communications US phone: +1 858 319 7135 EU phone: +45 2758 2601 [email protected] SOURCE Cardea Bio